Ryan Payne, MD
Urology · Salina, KSNPI 1750475638
Payments from drug & device makers
Across 239 payments — averaging $48.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$7K
- Dendreon Pharmaceuticals LLC$744
- Johnson & Johnson$533
- AbbVie$473
- Astellas Pharma US Inc$449
- Boston Scientific$258
- plus $2K from 35 others
What the payments were for
- Travel & lodging$1,71715%
- Food & beverage$5,17144%
- Education$4,76541%
- Gifts$90%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 22 | $7,271 |
| Dendreon Pharmaceuticals LLC | 22 | $744 |
| Johnson & Johnson | 29 | $533 |
| AbbVie(2 entities) | 35 | $473 |
| Astellas Pharma US Inc | 23 | $449 |
| Boston Scientific | 11 | $258 |
| Ambu Inc. | 5 | $179 |
| Pfizer | 10 | $177 |
| Medtronic | 6 | $146 |
| Axonics, Inc. | 8 | $130 |
| Sumitomo Pharma America, Inc. | 8 | $125 |
| Progenics Pharmaceuticals, Inc. | 5 | $110 |
| Urogen Pharma, Inc. | 4 | $92 |
| Olympus America Inc. | 5 | $86 |
| Urovant Sciences Inc | 4 | $77 |
| Teleflex LLC | 4 | $68 |
| Janssen Scientific Affairs, LLC | 2 | $65 |
| 180 Medical, Inc. | 3 | $57 |
| Bayer | 2 | $44 |
| Endo Pharmaceuticals Inc. | 3 | $43 |
| BD | 1 | $41 |
| Merck | 2 | $38 |
| Tolmar Pharmaceuticals, Inc. | 2 | $37 |
| Procept Biorobotics Corporation | 2 | $36 |
| Travere Therapeutics, Inc. | 2 | $33 |
| Cook Medical LLC | 2 | $33 |
| Telix Pharmaceuticals | 1 | $31 |
| Myovant Sciences Inc. | 2 | $30 |
| Immunitybio, Inc. | 1 | $30 |
| Neotract Inc. | 2 | $28 |
| Siemens Medical Solutions USA, Inc. | 1 | $26 |
| Tolmar, Inc. | 1 | $22 |
| Endo USA, Inc. | 1 | $21 |
| GE HealthCare | 1 | $19 |
| Calyxo, Inc. | 1 | $19 |
| Laborie Medical Technologies Corp. | 1 | $18 |
| KARL Storz Endoscopy-america | 1 | $18 |
| Coloplast | 1 | $16 |
| Therapeuticsmd, Inc. | 1 | $16 |
| Myriad Genetic Laboratories, Inc. | 1 | $15 |
| Civco Medical Instruments | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DA VINCI SP$4,500
- Da Vinci Surgical System$2,606
- PROVENGE$126
How this compares
$11,662 in reported general payments places this provider in the 80th percentile of 111 urology providers in Kansas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 16 | $241,778 |
| GemtesaVibegron | 108 | $51,765 |
| MyrbetriqMirabegron | 63 | $41,272 |
| Abiraterone Acetate | 25 | $26,363 |
| Potassium Citrate ErPotassium Citrate | 106 | $10,561 |
| Tamsulosin Hcl | 745 | $7,066 |
| Finasteride | 683 | $6,793 |
| Estradiol | 45 | $3,714 |
| Testosterone Cypionate | 41 | $1,930 |
| Solifenacin Succinate | 45 | $1,733 |
| Dutasteride | 75 | $1,603 |
| Oxybutynin Chloride ErOxybutynin Chloride | 56 | $1,162 |
| Tolterodine Tartrate ErTolterodine Tartrate | 13 | $601 |
| Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst | 35 | $494 |
| Prednisone | 33 | $347 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $533 | $241,77816 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $125 | $51,765108 claims |
| Astellas Pharma US IncMyrbetriq | $449 | $41,27263 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $65 | $26,36325 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 111 urology providers in Kansas.
Other urology in Salina
- Julianne RathbunSalina$6K
- Michael MatteucciSalina$3K
- Brian SmithSalina$3K
- William MauchSalina$2K
- Son NguyenMerriam$6.4M
- Timothy RichardsonWichita$5.3M
- Fadi JoudiWichita$2.3M
- Eugene LeeKansas City$2.2M
- Wilson MolinaKansas City$513K
- Jeffrey HolzbeierleinKansas City$341K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.